Intal
Links shared publicly online about this topic
Astellas Pharma to transfer Intal rights to Sanofi-aventis - News - Manufacturing
manufacturing.pharmaceutical-business-review.com — “Astellas Pharma is set to transfer the rights to distribute the anti-allergic drug Intal (sodium cromoglycate) to Sanofi-aventis effective on 1 January 2011.” View full resource at manufacturing.pharmaceutical-business-review.com
Most Recently Shared on October 21, 2010 at 1:42 am By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Astellas Pharma to transfer Intal rights to Sanofi-aventis - News - Manufacturing http://is.gd/gatRD
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Michael Blaiss, MD
Allergist. Past President of the American College of Allergy, Asthma, and Immunology
Advertisement
